AAL vs ALDX
AAL: A leading global airline operating one of the world's largest flight networks and loyalty programs. ALDX: Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on addressing regulatory feedback and securing capital for development and commercialization.
Side-by-side fundamentals
| Metric | AAL | ALDX | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $15.27 | $1.54 | |
| Market cap as of 2026-08-01 | $10.1B | $93M | |
| PEG as of 2026-08-01 | 0.42 | n/a | |
| Net margin as of 2026-08-01 | -0.6% | n/a | |
| Gross margin as of 2026-08-01 | +62.0% | n/a | |
| Operating margin as of 2026-08-01 | +1.6% | n/a | |
| ROE as of 2026-08-01 | +265.6% | -57.3% | AAL higher |
| ROA as of 2026-08-01 | -0.5% | -36.3% | AAL higher |
| Debt / equity as of 2026-08-01 | 157.71 | 0.36 | ALDX lower |
| Revenue growth (YoY) as of 2026-08-01 | +7.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +3.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-08-01 | 1.67 | 0.77 | |
| 1-year return as of 2026-07-31 close | +32.9% | -69.1% | AAL higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.